SCHEMBL935855

SCHEMBL935855

CC(=O)C1Cc2ccc(F)cc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.42
ACHE P22303 1/20 0.42
DPP4 P27487 5/20 0.39
DPP8 Q6V1X1 5/20 0.39
DPP9 Q86TI2 5/20 0.39
DPP7 Q9UHL4 4/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A4 P31645 1/20 0.38
CCR3 P51677 2/20 0.37
CA1 P00915 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4015666 0.83 PSEN1 (0.42) NOTUMACHEDPP4DPP8DPP9
SCHEMBL29443104 0.81 KMT2A (0.47) NOTUMACHEDPP4DPP8DPP9
SCHEMBL1340597 0.81 KMT2A (0.47) NOTUMACHEDPP4DPP8DPP9
SCHEMBL9688904 0.79 HSD17B1 (0.46) ACHECA1CA2
SCHEMBL7123106 0.79 NOTUM (0.41) NOTUMACHEDPP4CA1CA2
SCHEMBL27725838 0.79 NOTUM (0.37) NOTUMACHEDPP4DPP8DPP9
SCHEMBL28381288 0.79 SLC6A4 (0.42) NOTUMACHEDPP4DPP8DPP9
SCHEMBL16595782 0.78 HTR1D (0.38) NOTUMACHEDPP4DPP8DPP9
SCHEMBL12048612 0.78 PNMT (0.46) ADRA2AADRA2BADRA2C
SCHEMBL31637765 0.77 CA1 (0.61) HTR1DHTR1BPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2456749-B1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS REGENSBURG GMBH (DE) 2016-03-30 EP disclosed
US-8563766-B2 Indane derivatives for use as intermediates DSM PHARMA CHEMICALS (DE) 2013-10-22 US disclosed
US-20120190881-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS (DE) 2012-07-26 US disclosed
CN-102548951-A Indane derivatives as intermediates DSM PHARMA CHEMICALS REGENSBURG GMBH 2012-07-04 CN disclosed
EP-2456749-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM Pharma Chemicals Regensburg GmbH (DE) 2012-05-30 EP disclosed
US-8071635-B2 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors; ALLERGAN, INC. (US) 2011-12-06 US disclosed
US-8063086-B2 Modulators of alpha2B and/or alpha2C adrenergic receptors; alleviate chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain; 4-(substituted cycloalkylmethyl)imidazole-2-thione and 4-(substituted cycloalkenylmethyl)imidazole-2-thione compounds ALLERGAN, INC. (US) 2011-11-22 US disclosed
US-8063087-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds ALLERGAN, INC. (US) 2011-11-22 US disclosed
US-7960423-B2 selective to alpha2B and/or alpha2C adrenergic receptors, minimal cardivascular and/or sedatory activity; pain ALLERGAN, INC (US) 2011-06-14 US disclosed
WO-2011009928-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES DSM PHARMA CHEMICALS REGENSBURG GMBH (DE) 2011-01-27 WO disclosed
US-7569584-B2 4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same ALLERGAN, INC. (US) 2009-08-04 US disclosed
US-20080319013-A1 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND RELATED COMPOUNDS ALLERGAN, INC. (US) 2008-12-25 US disclosed
US-20080221186-A1 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds CHOW KEN 2008-09-11 US disclosed
US-20080097103-A1 IMIDAZOLE-2-THIONES CHOW KEN 2008-04-24 US disclosed
US-20080091028-A1 IMIDAZOLE-2-THIONES ALLERGAN, INC. (US) 2008-04-17 US disclosed
US-20080070945-A1 4-(2-METHYL-5,6,7,8-TETRAHYDRO-QUINOLIN-7-YLMETHYL)-1,3-DIHYDRO-IMIDAZOLE-2-THIONE AS SPECIFIC ALPHA2B AGONIST AND METHODS OF USING THE SAME ALLERGAN, INC. 2008-03-20 US disclosed
US-7345077-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2008-03-18 US disclosed
US-7323485-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2008-01-29 US disclosed
US-7276522-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2007-10-02 US disclosed
US-20070072926-A1 Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases ALLERGAN, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097103-A1 IMIDAZOLE-2-THIONES ADRB2, ADRA2C, ADRA2B NOTUM 3822/4885ACHE 526/4885DPP4 4273/4885
US-20120190881-A1 INDANE DERIVATIVES FOR USE AS INTERMEDIATES CYP1A1, CYP1A2, CYP1B1 NOTUM 2060/4885ACHE 876/4885DPP4 4497/4885
US-20080091028-A1 IMIDAZOLE-2-THIONES ADRB2, ADRA2C, ADRA2B NOTUM 3637/4885ACHE 818/4885DPP4 3671/4885
US-20080319013-A1 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND RELATED COMPOUNDS ADRB2, ADRA2C, ADRA2B NOTUM 3037/4885ACHE 714/4885DPP4 2724/4885
US-20080221186-A1 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds ADRB2, ADRA2C, ADRA2B NOTUM 3466/4885ACHE 662/4885DPP4 3138/4885
US-20080070945-A1 4-(2-METHYL-5,6,7,8-TETRAHYDRO-QUINOLIN-7-YLMETHYL)-1,3-DIHYDRO-IMIDAZOLE-2-THIONE AS SPECIFIC ALPHA2B AGONIST AND METHODS OF USING THE SAME ADRB2, ADRA2C, ADRA2B NOTUM 3320/4885ACHE 1722/4885DPP4 3171/4885
US-20070072926-A1 Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases ADRA2A, ADRA2B, ADRB2 NOTUM 3636/4885ACHE 325/4885DPP4 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.